Loading...
Loading...
Retrophin
RTRX today announced that it has agreed to
support the completion of a Phase II clinical trial of oxytocin for the
treatment of schizophrenia directed by Dr. David Feifel, Department of
Psychiatry, University of California, San Diego. The study will become
part of the company's clinical development program for Syntocinon™.
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in